Tag Archives: renin angiotensin system
October 2020 Br J Cardiol 2020;27:109–11 doi:10.5837/bjc.2020.031
Neprilysin inhibitors and angiotensin(1–7) in COVID-19
Nathalie Esser, Sakeneh Zraika
The issue regarding use of RAS blockers in the context of COVID-19 has previously been reviewed.1,2 Most recently, emerging data suggest no harm is associated with use of ACE inhibitors or ARBs in COVID-19.3,4 In this perspective, we discuss a related aspect that was first raised by Acanfora and colleagues,5 namely, the potential benefit of neprilysin inhibitors and their role in modulating levels of RAS components. Similar to the situation for ACE inhibitors and ARBs, it seems there are mixed opinions on the utility of neprilysin inhibitors in COVID-19. In a recent review, it was postulated that increasing neprilysin activity might mitigate
May 2006 Br J Cardiol 2006;13:174-6
The American Society of Hypertension 21st Annual Scientific Meeting
Martin Godfrey
No content available
July 2004 Br J Cardiol 2004;11:287-90
Diurnal rhythms, the renin-angiotensin system and antihypertensive therapy
Michael Schachter
No content available
March 2004 Br J Cardiol 2004;11:123-27
Inhibition of the renin-angiotensin system in diabetic patients – beyond HOPE
Anthony H Barnett
No content available
October 2002 Br J Cardiol 2002;9:533-7
Aldosterone antagonism: new ideas, new drugs
Mike Schachter
No content available
For healthcare professionals only
